Colin Miles

A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma

Alba A. Brandes, Santosh Kesari, Juan Manuel Sepúlveda-Sánchez et al. · Neuro-Oncology · 2016 · 271 citations · Full text

Medicine, Oncology, Pharmacology +17

Defining a therapeutic window for the novel <scp>TGF</scp>‐β inhibitor <scp>LY</scp>2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model

Ivelina Gueorguieva, Ann Cleverly, Anja J. Stauber et al. · British Journal of Clinical Pharmacology · 2013 · 79 citations · Full text

Medicine, Oncology, Pharmacology +17

Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine

David Capper, Andreas von Deimling, Alba A. Brandes et al. · International Journal of Molecular Sciences · 2017 · 31 citations · Full text

Medicine, Oncology, Pharmacology +17

TC‐2559 excites dopaminergic neurones in the ventral tegmental area by stimulating<i>α</i>4<i>β</i>2‐like nicotinic acetylcholine receptors in anaesthetised rats

Yun Wang, J. L. Sherwood, Colin Miles et al. · British Journal of Pharmacology · 2006 · 23 citations · Full text

Medicine, Neuroscience, Pharmacology +17

Disposition and metabolism of [ ¹⁴ C]-galunisertib, a TGF- <b>β</b> RI kinase/ALK5 inhibitor, following oral administration in healthy subjects and mechanistic prediction of the effect of itraconazole on galunisertib pharmacokinetics

Kenneth C. Cassidy, Ivelina Gueorguieva, Colin Miles et al. · Xenobiotica · 2017 · 11 citations

Medicine, Pharmacokinetics, Pharmacology +12